InBody Co.Ltd (041830) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of InBody Co.Ltd stock KRW 49,984, price KRW 42,050, upside +18.9%, quality 69 out of 100. Rating: undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.
How to read this chart
60‑month range 16,777 KRW – 70,800 KRW · fair‑value band 31,594 KRW – 69,025 KRW · the 42,050 KRW price screens below the 49,984 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 7, 2026.
Follow InBody Co.Ltd in your weekly email
Every Wednesday you see whether InBody Co.Ltd is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
InBody Co.,Ltd provides body composition analysis solutions worldwide. The company offers body composition analyzers, blood pressure monitors, stadiometers, and body water analyzers, as well as InBody dial and bands.
Show moreShow less
Its products are used in nephrology, liver disease, diabetes, nutrition, and rehabilitation applications. The company was formerly known as Biospace Co., Ltd. InBody Co.,Ltd was founded in 1996 and is headquartered in Seoul, South Korea.
Stock analysis
InBody Co.Ltd (041830) currently trades at 42,050 KRW, while our model-based Fair Value estimate is 49,984 KRW, implying the stock looks roughly 16% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 53,096 KRW per share, and 15 of the 26 models we run sit above the 42,050 KRW price.
Bear case: the Dividend Discount group reads lowest at 5,177 KRW, and 11 of the 26 models stay below the price. Data coverage for this calculation is medium.
Scenario range: 31,594 KRW (bear) to 69,025 KRW (bull), the price of 42,050 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 69/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
InBody Co.Ltd reported revenue of 234B KRW in FY2025 versus 138B KRW in FY2021, a compound +14.1%/yr. Reported net income was 30.6B KRW in FY2025, compounding −2.6%/yr from FY2021.
Key figures
Market cap 563B KRW (≈ $417M) Small · P/S ratio 4.01 · Dividend yield 1.8% · Net margin 23.5% · Return on equity 1,191% · Return on assets (EBIT) 14.1% (5-year average) · Operating margin 24.5% · Revenue (TTM) 155B KRW.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 77 out of 100 (low confidence).
What moves the price
The share trades about 41% below its 52-week high and 58% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −11% fair-value upside, at 19%, 041830 screens cheaper than that median.
Fair Value models
Bear31,594 KRWFair Value 49,984 KRWBull69,025 KRW
Price 42,050 KRW · Upside +18.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.100/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+14.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.9%
Start year 2020 (pandemic). Over 10 years: +13.0% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.4%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+12.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year+10.3%
Dividend (yield on the price)1.8%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.10.3% vs 7.2%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.18% → 16%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+6.1%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about +3.9% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Healthcare Equipment & Supplies” was too small, so the broader sector is used.)Health Care · 2276 stocks
Beats the sector median on 11/12 measures
Overall it ranks above its sector peers.
Valuation
Quality Score69 · Top 25%
Fair Value upside+18.9% · Top 25%
Profitability
Return on assets8.5% · Top 25%
Net margin (12 months)23.5% · Top 25%
Operating margin (12 months)24.5% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)17.7% · Above median
Dividend yield (12 months)1.8% · Above median
Balance sheet
Debt / equity0.01× · Below median
Valuation Multiplesvs Health Care median · lower = cheaper
P/B1.77× · Cheaper than median
P/S (12 months)3.64× · Pricier than median
Price / free cash flow (fiscal year)19.9× · Cheaper than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "InBody Co.Ltd Fair Value". https://www.fairvalue-calculator.com/stock/041830
Frequently asked questions
Is InBody Co.Ltd (041830) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of 49,984 KRW versus a price of 42,050 KRW, about +19% upside (undervalued).
What is the fair value of 041830?
Our model-based fair value for InBody Co.Ltd is 49,984 KRW (as of Nov 7, 2026), built from audited fundamentals. The current price: 42,050 KRW.
What is the quality score of 041830?
InBody Co.Ltd has a Quality Score of 69/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for InBody Co.Ltd (041830)?
Our model-based price target is the fair value of 49,984 KRW (as of Nov 7, 2026) from 26 valuation models. Cautious scenario 31,594 KRW, optimistic scenario 69,025 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the InBody Co.Ltd stock forecast for 2026?
Our models put fair value at 49,984 KRW, about +19% upside versus a price of 42,050 KRW (undervalued). Cautious scenario 31,594 KRW, optimistic scenario 69,025 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of InBody Co.Ltd (041830)?
InBody Co.Ltd reported trailing-twelve-month revenue of about 155B KRW (latest available figure, as of Nov 7, 2026).
Does InBody Co.Ltd pay a dividend?
InBody Co.Ltd currently shows a dividend yield of 1.81% relative to its recent price (as of Nov 7, 2026).
How much is the dividend of InBody Co.Ltd (041830)?
InBody Co.Ltd has a dividend yield of 1.8%. Our assessment: Safety not assessed. Payout ratio and cash coverage are not available, so we do not judge how safe this dividend is.
What growth is priced into InBody Co.Ltd (041830)?
For today's price to be fair in a discounted-cash-flow model, InBody Co.Ltd would have to grow free cash flow by +6.1 % per year for five years (discount rate 10.7 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +16.9 % per year. As of Nov 7, 2026.
What discount rate (WACC) does the fair value of 041830 use?
Our models discount InBody Co.Ltd at 10.7 %: a base by market capitalisation (small), damped by beta 0.69, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For InBody Co.Ltd that is +6.1 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (10.7 %) and the same formula as our fair value.
How much growth has InBody Co.Ltd (041830) delivered so far?
Over the past 5 years revenue at InBody Co.Ltd grew +16.9 % a year. The price currently implies free-cash-flow growth of +6.1 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of InBody Co.Ltd (041830) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into InBody Co.Ltd (+6.1 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of InBody Co.Ltd (041830)?
The free-cash-flow yield on the price is 5.53 %: that much free cash flow InBody Co.Ltd produces per unit of market value. When it exceeds the discount rate of our models (10.7 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of InBody Co.Ltd (041830)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For InBody Co.Ltd it is 49,984 KRW per share (as of Nov 7, 2026), against a price of 42,050 KRW. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is InBody Co.Ltd stock overvalued or undervalued in 2026?
As of Nov 7, 2026, 041830 trades below its calculated fair value: price 42,050 KRW, fair value 49,984 KRW, a gap of about +19% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 041830?
No. The price is what the market pays today (42,050 KRW); the fair value is what the company's own numbers justify (49,984 KRW). For InBody Co.Ltd the two are 7,934 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is InBody Co.Ltd worth?
The market values InBody Co.Ltd at about 563B KRW (market capitalisation, as of Nov 7, 2026). Per share that is 42,050 KRW; our models calculate a fair value of 49,984 KRW per share.
What do the bullish and bearish scenarios say about 041830?
Our models span a range for InBody Co.Ltd: cautious scenario 31,594 KRW, base 49,984 KRW, optimistic 69,025 KRW per share (as of Nov 7, 2026, price 42,050 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of InBody Co.Ltd (041830)?
Balance-sheet figures for InBody Co.Ltd (as of Nov 7, 2026): debt of 0.01 per unit of equity. They feed the Quality Score of 69/100, which measures business quality independently of the share price.
How far is 041830 from its 52-week high?
InBody Co.Ltd trades at 42,050 KRW, about 41% below its 52-week high of 70,800 KRW and 58% above the low of 26,586 KRW (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 49,984 KRW is for.
Which stocks are comparable to InBody Co.Ltd?
From the same area (Healthcare) we also value Value Added Technology Co, Mediana Co, Sewoon Medical Co, Meta Biomed Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is InBody Co.Ltd stock attractive at the current price?
The data as of Nov 7, 2026: price 42,050 KRW, calculated fair value 49,984 KRW (+19%), Quality Score 69/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 041830 calculated?
We run InBody Co.Ltd through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 49,984 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. InBody Co.Ltd currently trades 16% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of InBody Co.Ltd (041830)?
The closing price on Nov 6, 2026 was 42,050 KRW. Our model-based fair value is 49,984 KRW, about +19% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with InBody Co.Ltd right now?
A fairly wide model range (31,594 KRW to 69,025 KRW) leaves room in how you read the outcome. The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Key figures of InBody Co.Ltd
How large is the market capitalisation of InBody Co.Ltd (041830)?
The market capitalisation of InBody Co.Ltd is 563B KRW (≈ $417M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of InBody Co.Ltd (041830)?
The price-to-sales ratio of InBody Co.Ltd is 4.01 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of InBody Co.Ltd (041830)?
The dividend yield of InBody Co.Ltd is 1.8%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of InBody Co.Ltd (041830)?
The net margin of InBody Co.Ltd is 23.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of InBody Co.Ltd (041830)?
The return on equity (ROE) of InBody Co.Ltd is 1,191% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of InBody Co.Ltd (041830)?
On an EBIT basis the return on assets of InBody Co.Ltd is 14.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of InBody Co.Ltd (041830)?
The operating margin of InBody Co.Ltd is 24.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at InBody Co.Ltd (041830)?
Revenue at InBody Co.Ltd is growing +17.7% versus a year earlier (3y avg +13.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at InBody Co.Ltd (041830)?
Earnings per share at InBody Co.Ltd are growing +30.2% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch InBody Co.Ltd in the live analysis
One click puts InBody Co.Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 7, 2026